Skip to content

Aneuploidy Rates of in Vitro Matured Oocytes

Aneuploidy Rates of in Vitro Matured Oocytes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03860064
Acronym
IVM
Enrollment
60
Registered
2019-03-01
Start date
2019-03-27
Completion date
2019-09-30
Last updated
2019-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneuploidy

Brief summary

In general, nearly 85% of retrieved oocytes are mature and reproductively useful after the retrieval, whereas the remaining percentage are still at metaphase I or germinal vesicle stage (MI: 4% and GV: 11 %, respectively). The objective of our study is to assess if immature oocytes co-cultured with autologous cumulus cells is a safer strategy than just leaving the oocytes in standard culture.

Detailed description

Under controlled ovarian stimulation, patients with normal functional ovarian reserves produce a good number of oocytes at retrieval. However, in addition to quantity, oocyte maturity is an important variable for the success of reproductive technologies. In general, nearly 85% of retrieved oocytes are mature and reproductively useful, whereas the remaining percentage are still at metaphase I or germinal vesicle stage (MI: 4% and GV: 11 %, respectively). Due to the limited expectations held for in vitro maturation in said stimulated cycles, the rescue of immature oocytes is not widely used in current clinical practice and these oocytes are usually discarded due to the possibility of abnormal embryonic development or an increased rate of abortion. The objective of our study is to assess if immature oocytes co-cultured with autologous cumulus cells is a safer strategy than just leaving the oocytes in standard culture.

Interventions

OTHERNon intervention

Non

Sponsors

IVI Barcelona
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* 18-35-year-old women * BMI: \>18 and \< 30 kg/m2 * Normal female karyotype * Normal uterus and ovaries at transvaginal ultrasound

Exclusion criteria

* \> 35 years * PCO syndrome carriers * Null follicle aspiration * History of chemotherapy or radiotherapy

Design outcomes

Primary

MeasureTime frameDescription
Aneuploidy rateThe moment that the PB is extruded (between 1 hour and 50 hours after the denudation)Aneuploidy rate of the PB

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026